20. Belangenverstrengeling

Naam
Afgevaardige namens
Gilead
Jansen BMS
Abbvie Roche
MSD
Overig
J.E. Arends
NVHB
A,R
A
A,R
A,R
-
A
ViiV (A,R)
J.T. Brouwer NVH, NVMDL A
A
A
A
-
A
-
M.A.A. Claassen NIV -
-
-
-
-
-
-
D.M. Burger NVZA A,L A,L,R
A,R
A,L
R
A,L,R,C
-
J.P.H. Drenth NVH, comm Hepatologie NVMDL A,C,R A
A
A,R,C
-
A
Ipsen (R)
B. van Hoek
NVH -
A
A
A
-
A
Zambon (R), Chiesi (R), Astellas (R), Norgine (A)
A.I.M. Hoepelman NIV A, R -
A,R
-
-
A,R
ViiV (A, R)
P. Honkoop Comm Hepatologie NVMDL
A A
-
A
-
-
Will Pharma (A)
R.J. de Knegt
NVH/NVMDL A,L,R A,L,R
A,L,R
A,L,R,C
L,R
-
Norgine (A,L), Philip (R)
P.A.M. Kracht NIV -
-
-
-
-
-
-
K. Sebib Korkmaz NVMDL/NVH -
-
-
-
-
-
-
M.J. Sonneveld NVMDL/NVH A
-
A
-
A,L,C
-
-
H. van Soest Comm Hepatologie NVMDL
-
-
-
-
-
-
-
M. van der Valk NVHB A,R,L A,R
A
A
A
A,R
ViiV (A,R)
S. Willemse NVH, NVMDL A,L,R,C
L,R
A,L,R
A,R,C
L,R
R
-
A: Advisory Board; L: Lectures; R: Research; C: Consultancy


Index